Understanding the mechanisms of viral induced asthma: new therapeutic directions.
- Publisher:
- PERGAMON-ELSEVIER SCIENCE LTD
- Publication Type:
- Journal Article
- Citation:
- Pharmacology & therapeutics, 2008, 117, (3), pp. 313-353
- Issue Date:
- 2008-03
Closed Access
Filename | Description | Size | |||
---|---|---|---|---|---|
Understanding the mechanisms of viral induced asthma new therapeutic directions.pdf | Published version | 983.78 kB | Adobe PDF |
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
Full metadata record
Field | Value | Language |
---|---|---|
dc.contributor.author | Hansbro, NG | |
dc.contributor.author | Horvat, JC | |
dc.contributor.author | Wark, PA | |
dc.contributor.author | Hansbro, PM | |
dc.date.accessioned | 2021-01-06T00:06:24Z | |
dc.date.available | 2007-11-19 | |
dc.date.available | 2021-01-06T00:06:24Z | |
dc.date.issued | 2008-03 | |
dc.identifier.citation | Pharmacology & therapeutics, 2008, 117, (3), pp. 313-353 | |
dc.identifier.issn | 0163-7258 | |
dc.identifier.issn | 1879-016X | |
dc.identifier.uri | http://hdl.handle.net/10453/145099 | |
dc.description.abstract | Asthma is a common and debilitating disease that has substantially increased in prevalence in Western Societies in the last 2 decades. Respiratory tract infections by respiratory syncytial virus (RSV) and rhinovirus (RV) are widely implicated as common causes of the induction and exacerbation of asthma. These infections in early life are associated with the induction of wheeze that may progress to the development of asthma. Infections may also promote airway inflammation and enhance T helper type 2 lymphocyte (Th2 cell) responses that result in exacerbations of established asthma. The mechanisms of how RSV and RV induce and exacerbate asthma are currently being elucidated by clinical studies, in vitro work with human cells and animal models of disease. This research has led to many potential therapeutic strategies and, although none are yet part of clinical practise, they show much promise for the prevention and treatment of viral disease and subsequent asthma. | |
dc.format | Print-Electronic | |
dc.language | eng | |
dc.publisher | PERGAMON-ELSEVIER SCIENCE LTD | |
dc.relation.ispartof | Pharmacology & therapeutics | |
dc.relation.isbasedon | 10.1016/j.pharmthera.2007.11.002 | |
dc.rights | info:eu-repo/semantics/restrictedAccess | |
dc.subject | 1115 Pharmacology and Pharmaceutical Sciences | |
dc.subject.classification | Pharmacology & Pharmacy | |
dc.subject.mesh | Animals | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Respiratory Syncytial Viruses | |
dc.subject.mesh | Rhinovirus | |
dc.subject.mesh | Respiratory Tract Infections | |
dc.subject.mesh | Respiratory Syncytial Virus Infections | |
dc.subject.mesh | Picornaviridae Infections | |
dc.subject.mesh | Common Cold | |
dc.subject.mesh | Asthma | |
dc.subject.mesh | Disease Susceptibility | |
dc.subject.mesh | Macrolides | |
dc.subject.mesh | Adrenal Cortex Hormones | |
dc.subject.mesh | Angiogenesis Inhibitors | |
dc.subject.mesh | Interferon Type I | |
dc.subject.mesh | Adrenergic beta-Agonists | |
dc.subject.mesh | Viral Vaccines | |
dc.subject.mesh | Antibodies | |
dc.subject.mesh | Antioxidants | |
dc.subject.mesh | Antiviral Agents | |
dc.subject.mesh | Immunization, Passive | |
dc.subject.mesh | Adrenal Cortex Hormones | |
dc.subject.mesh | Adrenergic beta-Agonists | |
dc.subject.mesh | Angiogenesis Inhibitors | |
dc.subject.mesh | Animals | |
dc.subject.mesh | Antibodies | |
dc.subject.mesh | Antioxidants | |
dc.subject.mesh | Antiviral Agents | |
dc.subject.mesh | Asthma | |
dc.subject.mesh | Common Cold | |
dc.subject.mesh | Disease Susceptibility | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Immunization, Passive | |
dc.subject.mesh | Interferon Type I | |
dc.subject.mesh | Macrolides | |
dc.subject.mesh | Picornaviridae Infections | |
dc.subject.mesh | Respiratory Syncytial Virus Infections | |
dc.subject.mesh | Respiratory Syncytial Viruses | |
dc.subject.mesh | Respiratory Tract Infections | |
dc.subject.mesh | Rhinovirus | |
dc.subject.mesh | Viral Vaccines | |
dc.title | Understanding the mechanisms of viral induced asthma: new therapeutic directions. | |
dc.type | Journal Article | |
utslib.citation.volume | 117 | |
utslib.location.activity | England | |
utslib.for | 1115 Pharmacology and Pharmaceutical Sciences | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Science | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Science/School of Life Sciences | |
pubs.organisational-group | /University of Technology Sydney | |
utslib.copyright.status | closed_access | * |
dc.date.updated | 2021-01-06T00:06:15Z | |
pubs.issue | 3 | |
pubs.publication-status | Published | |
pubs.volume | 117 | |
utslib.citation.issue | 3 |
Abstract:
Asthma is a common and debilitating disease that has substantially increased in prevalence in Western Societies in the last 2 decades. Respiratory tract infections by respiratory syncytial virus (RSV) and rhinovirus (RV) are widely implicated as common causes of the induction and exacerbation of asthma. These infections in early life are associated with the induction of wheeze that may progress to the development of asthma. Infections may also promote airway inflammation and enhance T helper type 2 lymphocyte (Th2 cell) responses that result in exacerbations of established asthma. The mechanisms of how RSV and RV induce and exacerbate asthma are currently being elucidated by clinical studies, in vitro work with human cells and animal models of disease. This research has led to many potential therapeutic strategies and, although none are yet part of clinical practise, they show much promise for the prevention and treatment of viral disease and subsequent asthma.
Please use this identifier to cite or link to this item:
Download statistics for the last 12 months
Not enough data to produce graph